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Abstract
Background: Young women diagnosed with breast cancer are known to have a higher mortality rate from the
disease than older patients. Specific risk factors leading to this poorer outcome have not been identified. In the
present study, we hypothesized that iron deficiency, a common ailment in young women, contributes to the poor
outcome by promoting the hypoxia inducible factor-1a (HIF-1a and vascular endothelial growth factor (VEGF)
formation. This hypothesis was tested in an in vitro cell culture model system.
Results: Human breast cancer MDA-MB-231 cells were transfected with transferrin receptor-1 (TfR1) shRNA to
constitutively impair iron uptake. Cellular iron status was determined by a set of iron proteins and angiogenesis
was evaluated by levels of VEGF in cells as well as by a mouse xenograft model. Significant decreases in ferritin
with concomitant increases in VEGF were observed in TfR1 knockdown MDA-MB-231 cells when compared to the
parental cells. TfR1 shRNA transfectants also evoked a stronger angiogenic response after the cells were injected
subcutaneously into nude mice. The molecular mechanism appears that cellular iron deficiency elevates VEGF
formation by stabilizing HIF-1a. This mechanism is also true in human breast cancer MCF-7 and liver cancer HepG2
cells.
Conclusions: Cellular iron deficiency increased HIF-1a, VEGF, and angiogenesis, suggesting that systemic iron
deficiency might play an important part in the tumor angiogenesis and recurrence in this young age group of
breast cancer patients.
Background
Young women (< 45 years old) diagnosed with breast
cancer are well known to have a higher risk of dying
from the disease than older patients because of greater
early recurrence rates, increased aggressiveness, and
mostly estrogen receptor (ER), progesterone receptor
(PR) and human epidermal growth factor receptor 2
(Her2) negative or triple negative breast tumors [1,2].
The specific risk factors contributing to this poorer out-
come in young patients have not been identified.
Although a decline in total breast cancer cases was
recently reported, a plot of age-specific breast cancer
rates shows a decrease only among women >45 years
old [3]. This dilemma calls for new research on identifi-
cation of additional risk factors in this young group of
patients.
Using data initially collected from the New York Uni-
versity Women’s Health Study, we observed that serum
iron and ferritin levels are significantly lower in pre-
than in postmenopausal women [4]. A typical character-
istic of young pre-menopausal women is the presence of
menstrual cycle. Through complex interactions of
hypothalamic-pituitary-ovarian (HPO) axis, the pituitary
gland stimulates the ovaries to mature and release an
egg every month [5,6]. When the egg is not fertilized,
the endometrial matrix prepared for egg fertilization is
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young females have higher dietary requirements for iron
than males and older females to prevent iron deficiency
[7]. The final stage of iron deficiency is iron deficiency
anemia (IDA). IDA has been known to the medical pro-
fession for several centuries as the condition in which a
person has inadequate amounts of iron to meet body’s
demands [8]. In developing countries, about 50% of all
women of childbearing age have IDA and, iron defi-
ciency is also common in young women of industria-
lized countries, particularly in poorer, less educated, and
minority populations [9,10]. Clearly, iron deficiency is a
relevant health issue in young women, but its relation-
ship to poor breast cancer outcomes has not been inves-
tigated to date.
Iron is an essential metal for all living organisms parti-
cipating in cellular processes, such as DNA synthesis,
enzyme functions, and oxygen transport. Cellular iron
metabolism is homologous among most cell types; cellu-
lar iron homeostasis is primarily mediated by transferrin
(Tf), transferrin receptor-1 (TfR1), and ferritin [11-13].
Tf is an iron transport protein with two iron-binding
sites and is mainly found in the bloodstream, from
which it circulates and delivers iron throughout the
body. TfR1 is a ubiquitous membrane protein forming a
complex with Tf, which initiates membrane endocytosis
and serves as a major cellular iron uptake pathway.
Excess iron within cells is stored in ferritin. When cells
are iron deficient, iron regulatory proteins (IRPs) bind
to iron responsive elements (IRE) in the 3′ untranslated
region (UTR) of TfR1 mRNA as well as 5′ UTR of ferri-
tin mRNA. The IRP binding to 3′-UTR results in TfR1
upregulation and increased iron uptake, but its binding
to 5′-UTR of ferritin leads to its downregulation and
decreased iron storage [12,14].
Iron depletion in cells by iron chelator desferoxamine
mesylate (DFO) has been shown to increase hypoxia-
inducible factor-1alpha (HIF-1a) [15,16]. HIF-1a is a
critical transcription factor for the regulation of vascular
endothelial growth factor (VEGF), a potent inducer of
tumor angiogenesis and metastasis [17]. However, direct
evidence of iron deficiency on VEGF is lacking and the
effect of iron deficiency on tumor angiogenesis has not
yet been studied. We have hypothesized that, in young
premenopausal women, an iron deficiency caused by
menstruation stabilizes HIF-1a, which increases the for-
mation of VEGF. This mechanism results in premeno-
pausal women being more susceptible to angiogenesis
and, consequently, leads to a high recurrence of breast
cancer [18]. To provide proof of the concept that iron
deficiency plays a role in angiogenesis, we used shRNA
techniques in the present study to knockdown TfR1
levels in the triple negative breast cancer MDA-MB-231
cells. Because TfR1 is the gatekeeper of iron uptake,
knocking down TfR1 is similar to closing the door for
iron entry; it physically disables iron uptake and causes
stable iron deficiency in cells, thus mimicking IDA. Our
results showed that iron deficiency in cells increased the
angiogenic potential of the cells.
Results
TfR1 shRNA knockdown causing cellular iron deficiency
and decreasing cellular responses to iron modulation
Cellular iron deficiency was achieved by either transi-
ently or stably transfecting MDA-MB-231 cells with
TfR1 shRNA expression vectors of L1, L2, L3, or their
mixtures (e.g., L1, 2, 3, a mixture of the three oligonu-
cleotides). Effective TfR1 knockdowns as confirmed by
Western blot were shown in Figure 1A and the degrees
of knockdown relative to the parental and nonsense
control cells were shown in Figure 1B. It can be seen
that cells stably-transfected with the L3 shRNA vector
produced an 80% knockdown in TfR1 and this transfec-
tant was selected for further studies.
Figure 1C shows that ferritin levels were decreased by
50% in the L3 TfR1 knockdown cells as compared to
the nonsense control cells. When compared to the par-
ental cells with baseline levels of ferritin at 22.1+1.5 ng/
mg, a knockdown of 65% was observed. Iron chelation
by DFO or hypoxic exposure further lowered ferritin
levels in the L3 TfR1 knockdown cells (bars 3&5). As
expected, iron supplementation caused elevation in ferri-
tin levels in the L3 cells grown under either normoxia
or hypoxia (bars 4&6). However, ferritin levels in the L3
cells treated with iron were still significantly lower than
the background levels of ferritin in the nonsense trans-
fected MDA-MB-231 cells without iron treatment.
These results indicate that the L3 TfR1 knockdown cells
are under iron-deficient conditions and are less respon-
sive to iron modulation either by chelation or by
supplementation.
TfR1 knockdown cells enhancing VEGF production and in
vivo angiogenesis
Considering the high prevalence of iron deficiency in
young women and the high tumor recurrence in young
breast cancer patients [7,19], association of cellular iron
deficiency with VEGF levels and angiogenesis were
investigated. Figure 2A shows that background levels of
VEGF in the iron deficient TfR1 knockdown L3 cells
were approximately 2-fold of those in the parental and
nonsense control (L-) cells (bar 4 vs 1&3). Hypoxia sig-
nificantly induced VEGF production in both parental
and TfR1 knockdown L3 cells. DFO also increased
VEGF in the TfR1 knockdown cells, although the differ-
ence was not statistically significant. Figure 2B shows
that parental, nonsense, and TfR1 knockdown cells all
initiated angiogenic responses by recruiting larger and
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Page 2 of 11more branched blood vessels resulting in higher vascular
density at the injection site (panels B-G) when com-
pared to the non-treated site (panel A). Nonsense con-
trol (panels D and E) displayed a greater magnitude of
angiogenic responses than parental MDA-MB-231 cells
did (panels B and C). Most interestingly, TfR1 knock-
down L3-derived xenografts (panels F and G) caused the
strongest response among the three treatment groups,
indicating that iron-deficient cells possess enhanced
angiogenic potential.
Effects of hypoxia and iron supplementation on LMW
iron and ferritin
Anemia is marked by decreased numbers of red blood
cells and often results in hypoxia in the breast [20]. To
mimic in vivo anemic condition, in vitro hypoxia at 1%
O2 was used. Its effects on cellular iron homeostasis
were studied in various non-transfected cancer cells,
which were more pathophysiologically relevant than the
TfR1 knockdown cells. Figure 3A shows that back-
ground levels of LMW iron were much higher in the
HepG2 cells originated from liver than in the MCF-7 or
MDA-MB-231 cells originated from breast. Hypoxia sig-
nificantly decreased levels of LMW iron in all three
types of cells. It is noteworthy that iron given concur-
rently with hypoxic exposures increased LMW iron
levels as compared to the hypoxic controls in HepG2
cells. However, the LMW iron in cells treated with
hypoxia and iron was still below those of the control
normoxic cells without iron treatment (16.1 ± 1.9 vs
21.2 ± 0.8 nmol/mg protein).
Figure 3B shows that, similar to the trend observed in
LMW iron levels, hypoxia caused a significant decline in
ferritin levels in MCF-7, MDA-MB-231, and HepG2
cells. The basal ferritin levels were lower in both MCF-7
and MDA-MB-231 than in HepG2 cells. However,
breast cancer cells are more sensitive to iron treatments.
For example, levels of ferritin in MCF-7 cells were
0.0
5.0
10.0
15.0
20.0
25.0
n
g
 
F
t
/
 
m
g
 
p
r
o
t
e
i
n
+
*
C
* * B
L1          L3      Parental    L1,2,3      L-
β β-tubulin
TfR1
A
Lanes           1           2         3          4          5
L-
L3
Normoxia
Hypoxia
DFO
Fe 
+            - - - - -
- +           +            +           +           +
+           +           +            +            - -
- - - - +           +
- - +            - - -
- - - +            - +
Bar             1              2             3               4               5              6
0
20
40
60
80
100
L1 L3 Parental L1,2,3 L-
%
 
o
f
 
P
a
r
e
n
t
a
l
 
T
f
R
1
Figure 1 TfR1 knockdown causes iron deficiency and decreases responses to iron modulations in MDA-MB-231 cells. A: TfR1 levels in
the parental MDA-MB-231 cells and TfR1-silenced transfectants. Lanes 1-2 represent stable transfectants, while lanes 4-5 illustrate TfR1 levels in
cells collected after 24-h transient transfection. Lane 1: shRNA#1 (L1); lane 2: shRNA #3 (L3); lane 3: parental MDA-MB-231cells (control); lane 4: a
mixture of shRNAs # 1, 2, & 3 (L1,2,3); lane 5: nonsense shRNA control (L-). B: Means of two densitometric analyses based on two independent
transfection experiments. C: nonsense (L-) and TfR1 knockdown (L3) MDA-MB-231 cells were subjected to different treatments: DFO (0.5 mM; 6
h); hypoxia (1% O2, 6 h); iron (50 μM FAC, 6 h), and ferritin was quantitated by ELISA. Bars represent means ± SD of three independent
experiments (n = 3).
+Significantly different from L- nonsense controls (p < 0.05). * Significantly different from L3 normoxic controls (p < 0.05).
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hypoxia, respectively. In contrast, ferritin increases in
HepG2 cells treated with iron were less than 50% under
normoxic and hypoxic conditions.
Hypoxia increasing levels of TfR1 and IRP binding
Figure 4A shows that iron chelation by DFO increased
TfR1 levels in MDA-MB-231 cells, while iron supple-
mentation decreased TfR1 in both MDA-MB-231 and
MCF-7 cells. Figure 4B displays that hypoxia increased
levels of TfR1 in MDA-MB-231 cells. The addition of
iron immediately prior to the hypoxia exposure only
slightly, if any, lowered the hypoxia-induced TfR1
increases. Figure 4C shows that DFO greatly increased
IRP binding in MDA-MB-231 cells, while iron supple-
mentation decreased it. IRP binding was low under nor-
moxia and its binding was minimally affected by
variable Tf saturation rates (either apo-Tf without iron
or holo-Tf with 100% iron saturation to its two binding
sites) (Figure 4C), suggesting that iron stored in trans-
ferrin is not as bioavailable as the inorganic iron in IRP
regulation. Figure 4D shows that 6-h hypoxic exposure
greatly increased IRP binding, giving results similar to
that of iron chelation by DFO. Again, iron supplementa-
tion (50 μM, 12-h pretreatment) reduced IRP binding
and brought hypoxia-induced IRP binding back to its
baseline normoxic levels. Together, these results suggest
that hypoxia causes cellular iron deficiency by decreas-
ing LMW iron and ferritin and increasing TfR1 and IRP
binding. Iron supplementation can partly negate these
hypoxia-induced changes in iron status.
Effect of cellular iron deficiency on HIF-1a stabilization
Figure 5A reveals that normoxic MDA-MB-231 cells
had a faint staining of HIF-1a, while a 6-h treatment
with 0.5 mM DFO under normoxia or a 6-h hypoxia
Figure 2 VEGF production and in vivo angiogenesis by parental, nonsense, and TfR1 knockdown MDA-MB-231 cells. (A) Levels of VEGF
in tissue culture media of parental, nonsense (L-), and TfR1 knockdown (L3) cells treated with hypoxia or DFO. Bars represent the means + SD
from four independent experiments (n = 4). (B) Matrigel plug xenografts (grown from MDA-MB-231 cells inoculated with Martigel™ into nude
mice) and surrounding tissue were excised from the flanks after 72 h. Tissues were visually examined for the degree of vasculature recruitment
to the xenograft site and arrows indicate neovascularization penetrating into the xenograft. Panel A: non-injected tissue; Panels B and C: parental
cells; Panels D and E: nonsense shRNA-transfected cells (L-); Panels F and G: TfR1 shRNA stably-transfected cells (L3). * Significantly different from
their respective controls (p < 0.05).
+Significantly different from the parental cells (p < 0.05).
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of cells with an anti-TfR1 antibody at a concentration of
10 μg/ml also resulted in HIF-1a stabilization. To test
whether iron is capable of altering HIF-1a levels, cells
were treated with iron and HIF-1a assessed. Figure 5B
shows that iron supplementation under hypoxia leads to
HIF-1a destabilization as compared to the hypoxic
controls.
Effects of hypoxia and iron supplements on VEGF and in
vitro angiogenesis
Figure 6A shows that DFO and hypoxia significantly
increased VEGF levels in MDA-MB-231 cells when
compared to the controls, as did cobalt, a metal ion
used as a positive control for HIF-1a stabilization [21].
Interestingly, iron supplementation caused significant
decreases in VEGF levels under hypoxia, suggesting that
iron counteracts HIF-1a stabilization and, thus, possibly
prevents the processes leading to angiogenesis. To con-
firm this finding, a co-culture system was used with
trans-well membrane inserts containing HepG2 or
MDA-MB-231 cells placed in the wells containing BCE
cells. As shown in Figure 6B, BCE cells co-cultured with
cancer cells under normoxia did not display morpholo-
gical changes (panels A and D), similar to quiescent
BCE cells under normoxia forming a typical cobblestone
monolayer on gelatin-coated surfaces (panel G). When
BCE cells were cultured alone under hypoxia they
appeared quite resilient to hypoxic effects with no visi-
ble changes in cell morphology (panel H). However,
BCE cells co-cultured with cancer cells under hypoxia
showed significant changes in cell morphology (panels B
and E). Upon activation, BCE cells became spindle-
shaped and arranged in patterns similar to cells treated
with basic fibroblast growth factor (panel I). Interest-
ingly, when co-cultures were pretreated with iron under
hypoxia, hypoxia-induced BCE activation was greatly
diminished (panels C and F). The morphology of the
iron- and hypoxia-treated BCE cells remained similar to
that of the cells under normoxic co-culture conditions.
Discussion
Estrogen and family history are two of the most signifi-
cant and well-characterized risk factors for breast can-
cer. However, family history and estrogen cannot fully
explain the higher breast cancer recurrence rates and
greater aggressiveness with mostly triple negative breast
tumors in young, pre-menopausal women as compared
to the older post-menopausal women [22-24]. Because
of high prevalence of iron deficiency in young women
[7], we have previously hypothesized that iron deficiency
may play an important role in the poor outcome of
young breast cancer patients [18]. Here we provide evi-
dence that cellular iron deficiency contributes to HIF-1a
stabilization, VEGF formation, and angiogenesis, all of
which are important in carcinogenesis, metastasis, and
breast cancer recurrence [25].
To date, most research involving iron in cancer has
been focused on iron overload causing oxidant-mediated
cancer promotion [26]. Our contention that iron defi-
ciency plays a role in breast cancer recurrence, appears
contradictory to the findings that iron overload contri-
butes to cancer [26]. However, there are important dif-
ferences that separate the two lines of investigations and
their conclusions. First, the aforementioned studies
examined the role of iron overload in cancer initiation
and promotion stages, for example, by fortifying diet
with iron in the presence or absence of a carcinogen
[27-29]. Second, epidemiological studies have examined
the iron status of the whole body attempting to link
Figure 3 Hypoxia mediates cellular iron deficiency by
decreasing in LMW iron and ferritin levels. HepG2, MDA-MB-231,
and MCF-7 cells were exposed to iron (100 μM FeSO4) immediately
prior to hypoxia (1% O2). After 6 h treatment, LMW iron was
determined by calcein assay (A) and ferritin levels by ELISA (B). Data
points are means ± SD of four independent experiments (n = 4).
* Significantly different from normoxic controls (p < 0.05).
+
Significantly different from respective normoxic or hypoxic controls
without iron treatments (p < 0.05).
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ment [26,30]. The present study focused on the other
end of the iron spectrum and examined how cellular
iron deficiency in cancer cells could affect signal trans-
duction pathways leading to tumor angiogenesis, a key
step necessary for cancer metastasis and its recurrence.
It is well known that when a new vasculature forms
and penetrates into the tumor core, primary tumor cells
can enter into the circulation and form secondary
tumor in distant organs. Once the tumors recur, the dis-
ease becomes incurable resulting in a high death rate.
To test our hypothesis [18], triple negative MDA-
MB-231 cells were stably-transfected with TfR1 shRNA
and used as iron deficient cancer cells. This mild TfR1
knockdown was not lethal and provided the most appro-
priate conditions to prove our hypothesis because: (a)
cellular iron homeostasis is mostly maintained by TfR1
(iron uptake) and ferritin (iron storage) [11,31,32], and
unaltered cells can readily adapt to iron level changes in
the environment using endogenous IRPs, which can
alter mRNA stability, transcription, and translation of
TfR1 and ferritin; (b) cells “primed” under iron deficient
in vitro culture conditions or even 3 D tissue culture
can reach iron equilibrium in the in vivo environment
once these cells are injected into the animals [33]. In
this study, we found that stable TfR1 knockdown cells
were constitutively iron-deficient as revealed by the
decreased levels of ferritin, a hallmarker of iron status
(Figure 1C).
HIF-1a and VEGF were used as the endpoints of the
present study because either or both can elicit an array
of effects, from initiating angiogenesis to tumor metasta-
sis, [17,34]. Overexpression of VEGF by MCF-7 cells
was shown to promote estrogen-independent tumor
Figure 4 Hypoxia mediates cellular iron deficiency by increasing TfR1 and IRP binding. MDA-MB-231 and MCF-7 cells were exposed to Fe
(FAC, 50 μM) or DFO (500 μM). Co-treatments were administered 2 h prior to the initiation of hypoxic exposures (37°C, 6 h). Thirty μg total
protein/sample were immunoblotted for TfR1 determination (A and B). IRP binding in MDA-MB-231 cells was assessed by EMSA (C). Means of
two densitometric analyses were from the IRPs binding experiments (D). Bars represent % IRP binding in samples treated in the absence of ME
in comparison to +2-ME controls (n = 2).
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Page 6 of 11growth in vivo [35]. Patients with early stage breast can-
cer who have tumors with elevated levels of VEGF were
reported to have a higher likelihood of recurrence or
death than patients having tumors with a low angiogenic
potential [25]. VEGF and VEGF receptors have proven
effective targets for current oncology therapies. How-
ever, whether iron deficiency is related to VEGF and
angiogenesis is unclear, and if yes, molecular mechanism
remains unknown. Here, we showed that iron deficient
cells by knocking down TfR1 produced more VEGF and
induced higher angiogenesis in nude mice than parental
and nonsense control cells (Figure 2). Our results are in
agreement with the previous study showing that TfR1
antibody, which specifically blocks the binding region of
TfR1 for transferrin, inhibited breast cancer cell prolif-
eration [36] and increased VEGF formation [37]. Addi-
tionally, we showed that iron chelation by DFO or
blocking iron uptake through TfR1 antibody stabilizes
HIF-1a under normoxic conditions (Figure 5). These
results stress the importance of iron deficiency in the
process of HIF-1a stabilization, possibly by inhibiting
HIF degrading prolyl-4-hydroxylases [38,39]. Whether
these iron deficient cells with higher potentials of
angiogenesis are more capable of metastasizing into
other organs await further investigations.
Anemia is functionally defined as having inadequate
numbers of red blood cells to maintain tissue oxygena-
tion. It has been shown that hypoxia is more intensified
in young and anemic breast cancer patients [20]. This
led us to investigate how hypoxia affects cellular iron
homeostasis. Our results showed that hypoxia decreases
levels of LMW iron in HepG2, MCF-7, and MDA-MB-
231 cells (Figure 3). This suggests a strong iron demand
during hypoxic exposures [40]. Although the overall
trends of hypoxia-mediated LMW iron decreases were
the same, HepG2 cells derived from human hepatocarci-
noma had significantly higher LMW iron content than
breast cancer cells. These differences may stem from
differences in iron metabolism profiles between the ori-
ginating tissues of the cell lines. Hepatocytes are known
for having high iron content because of the liver’sr o l e
in clearing and processing aged red blood cells. Interest-
ingly, breast cancer cells were much more responsive to
iron supplementation than HepG2 cells were, as shown
by changes in levels of ferritin (Figure 4B).
To confirm that the observed changes in ferritin and
TfR1 are a result of hypoxia-mediated iron decrease,
IRP binding to IRE was determined (Figure 4). Our
results showed that IRP binding to IRE increased during
hypoxia, while iron supplementation decreased IRP
binding. The IRP binding patterns in these two experi-
ments suggest that decreases in iron levels during
hypoxia caused a shift in iron metabolism to a state
favoring iron uptake and signaling cellular iron defi-
ciency [41,42]. Our results, along with the established
findings of HIF-mediated increase in TfR1 expression
[43], indicate that IDA induces hypoxia and stabilizes
HIF-1a and, in turn, hypoxia increases cellular iron
uptake to combat iron deficiency through negative feed-
back of the hypoxic conditions [44].
To further associate iron deficiency with HIF-1a,
VEGF, and angiogenesis, we showed that iron supple-
mentation caused a destabilization of HIF-1a (Figure
5B), a result which supports the idea that iron deficiency
contributes to HIF-1a induction and stabilization. The
effects of iron supplementation also extended beyond
cellular HIF stabilization and into downstream HIF sig-
naling, which lead to a lower level of VEGF and a
decline in the in vitro angiogenesis (Figure 6).
Conclusions
Our study is distinct from previous studies on iron over-
load and its contribution to cancer initiation and pro-
motion via oxidative stress pathways [26]. Our study
has demonstrated an important role for cellular iron
deficiency in HIF-1a stabilization, VEGF formation, and
angiogenesis, suggesting that systemic iron deficiency
Figure 5 HIF-1a stabilization in MDA-MB-231 cells by various
treatments. A: normoxia, hypoxia (1% O2, 6 h), anti-human TfR1
antibody (Ab, 10 μg/ml, 24 h), or 0.5 mM DFO (6 h). B: normoxia,
hypoxia (1% O2, 6 h), and hypoxia with Fe pre-treatment (50 μM, 3
h). Samples were analyzed by Western blotting and co-stained for
b-tubulin. One representative gel from three independent
experiments is shown.
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them more susceptible to tumor recurrence through the
same mechanism.
Methods
Chemical reagents
DFO, ferric ammonium citrate( F A C ) ,f e r r o u ss u l f a t e
heptahydrate (FeSO4￿7H 2O), b-mercaptoethanol (ME),
agar, and DNA ligase kit LIG-1 were purchased from
S i g m a( S t .L o u i s ,M O ) .O t h e rr e a g e n t sw e r e :S D S - T r i s -
HCl or non-denaturing polyacrylamide gels, nitrocellu-
lose membranes, (Bio-Rad Laboratories, Hercules, CA);
M-PER mammalian protein extraction reagent, calcein
(Molecular Probes); mini-Prep kit for vector DNA
isolation (Qiagen); anti-human TfR1 antibody (Research
Diagnostics, Flanders, NJ); Lipofectamine™ 2000 (Invitro-
g e n ,C a r l s b a d ,C A ) ;a n t i - H I F - 1 a antibody (BD Bios-
ciences, Palo Alto, CA); shRNA vector sequences,
pSilencer expression vector kit, RNA isolation kits,
DNA-free and RNAqueous (Ambion, Inc., Austin, TX).
Cell culture
Human triple negative breast cancer cell line MDA-MB-
231 was used for shRNA knockdown. For comparison,
human breast cancer ER
+ MCF-7 cells and human hepa-
tocarcinoma HepG2 cells with high background levels of
intracellular iron were also tested (ATCC, Manassas,
VA). Bovine capillary endothelial (BCE) cells, a kind gift
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Figure 6 VEGF levels in culture media of MDA-MB-231 cells and in vitro angiogenesis following various treatments. (A): Tissue culture
media from parental MDA-MB-231 cells were collected for VEGF measurements by ELISA; bars represent means + SD of four independent
experiments (n = 4). (B): Panels A-C: BCE cells co-cultured with HepG2 cells under normoxia; hypoxia; or hypoxia with 50 μM FAC. Panels D-F:
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Eckard et al. Cancer Cell International 2010, 10:28
http://www.cancerci.com/content/10/1/28
Page 8 of 11from Dr. Paolo Mignatti, were used for in vitro angio-
genesis (Department of Cell Biology, NYU School of
Medicine). Growth of each cell line was initiated with
the recommended culture conditions from the supplier.
All cell lines were then adapted to alpha-minimal essen-
tial medium (a-MEM) supplemented with 5% FBS, 2
mM L-glutamine, and 1X antibiotic/antimycotic solu-
tion. This measure was taken to prevent confounding
outcomes resulting from changing medium during co-
culture experiments. a-MEM was the main culture
medium because a-MEM is essentially iron-free, thus
providing maximal control of the iron levels (by supple-
mentation) in the culture environment.
Unless otherwise noted, the initial growth medium
was removed 18-24 h prior to experiments and replaced
with the iron-free a-MEM containing serum-replace-
ment supplement at 5 μg/l selenium, 10 mg/l insulin,
5.5 mg/l transferrin, and 2 mg/l ethanolamine. These
additives allowed cells to be maintained and even propa-
gated without serum for periods ranging from 72 h to
over a week. Cells were maintained in a humidified tis-
sue culture incubator at 37°C under 5% CO2.N o r m o x i a
exposures were carried out in the same incubator, while
hypoxic exposures were performed in a specially
designed exposure system with hypoxic gas (1% O2,5 %
CO2, and N2 balance).
TfR1 knockdown in MDA-MB-231 cells by shRNA
Three sequences of shRNA duplexes for human TfR1 as
well as control shRNA were purchased from Ambion
Inc. (Austin, TX). The TfR1 shRNA oligonucleotide
sequences were as follows:
L1: 5′-GATCCGGCCTTAATATGTTAACCTTTCAA-
GAGAAGGTTAACATATTAAGGCCTTA-3′
L2: 5′-GATCCGGCCAATGTCACAAAACCATT-
CAAGAGATGGTTTTGTGACATTGGCCTT A-3′
L3: 5′-GATCCGGTGTAGTGGAAGTATCTGTT-
CAAGAGACAGATACTTCCACTACACCTT A-3′
After ligating into a pSilencer 4.1-CMV neo vector,
MDA-MB-231 cells were seeded into 24-well plates and
cultured until about 50% confluent, then transfected
with 80 pmol TfR1 shRNA in Lipofectamine™ 2000 for
24 h according to the manufacturer’s instructions. Cells
treated with Lipofectamine™ 2000 alone and control
non-silencing shRNA were used as mock-transfected
controls. After 24 h, transiently-transfected cells were
used for some biochemical measurements and the
remaining cells were transferred to 25-cm
2 flasks for
selection. Stably-transfected TfR1 knockdown cells (L1-
L 3 )a sw e l la sn o n s e n s ec o n t r ol cells (L-) were selected
with neomycin at 2 mg/ml [45]. To verify TfR1 suppres-
sion, transfected cells were scrapped, homogenized, and
analyzed by Western blot.
In vivo angiogenesis using TfR1 shRNA knockdown cells
Three groups, each consisting of four 6-week old female
nude mice (Jackson Labs, Bar Harbor, ME) were treated
as follows: parental MDA-MB-231, MDA-MB-231 cells
stably-transfected with nonsense shRNA vector (L-), and
MDA-MB-231 cells stably-transfected with TfR1 shRNA
vector (L3). After harvesting, 2.5 × 10
6 cells were sus-
pended in 0.2 ml of 1:1 (vol:vol) mixture of PBS and the
same batch of Matrigel™. Cells were inoculated subcuta-
neously (0.2 ml) into both flanks of the nude mice.
Seventy-two hours post-inoculation, the subcutaneous
Matrigel plugs and skin surrounding the injection site
were excised, trans-illuminated and photographed.
Iron regulatory proteins (IRPs) electro-mobility shift assay
(EMSA)
The binding activities of IRPs to IRE were examined by
EMSA [46,47]. Following treatment, MDA-MB-231 cells
were lysed in a lysis buffer containing 10 mM Hepes
(pH 7.5), 3 mM MgCl2, 40 mM KCl, 5% glycerol, 0.3%
NP-40, and a complete protease inhibitor cocktail. The
32P-labeled IRE probe was synthesized by in vitro tran-
scription using the linearized pSPT-fer plasmid as the
template (a kind gift from Dr. L.C. Kühn, ISREC, Swit-
zerland), which contains human ferritin H-chain IRE.
After dividing samples into two equal parts, 2-mercap-
toethanol (2-ME) was added to one part of the sample
at a 2% final concentration. The addition of 2-ME cre-
ates a reducing environment, which facilitates maximal
binding of all present IRP proteins, and was used as the
internal control for IRP binding normalization. The two
samples (+/- 2-ME; 2 μg proteins each) were incubated
at room temperature with an excess amount of
32P-
labeled IRE probe (4 × 10
4 cpm) in 20 μl reaction buffer
(10 mM Hepes, pH 7.5, 3 mM MgCl2,4 0m MK C l ,5 %
glycerol, 0.07% NP-40, and a complete protease inhibitor
cocktail). After 20 min incubation, 1 unit RNase and
100 μg heparin were added, and the mixture was incu-
bated for an additional 10 min period. The reaction
mixture was separated on a 5% non-denaturing polya-
crylamide gel. The gel was dried and the amount of
radioactive material assessed by exposure to X-ray film.
The IRP binding was calculated by comparing the band
density of the sample without 2-ME to the sample with
2-ME.
Analysis of low molecular weight (LMW) iron
Levels of LMW iron in cells were determined using an
iron-sensitive fluorescent calcein as previously described
[48]. Briefly, calcein binds iron stoichiometrically, with
its fluorescence quenched upon calcein-Fe complex for-
mation. By adding DFO, the fluorescence specifically
quenched by iron can be regenerated. Therefore, the
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sample with and without DFO is directly proportional
to the amounts of LMW iron. The levels of LMW iron
are expressed as nmol iron/mg protein.
Determination of TfR1 and ferritin
TfR1 levels were measured by Western blot as follows:
cell lysates (30 μg protein) were subjected to 12% SDS-
polyacrylamide gel electrophoresis. After transferring
onto nitrocellulose membranes, the membranes were
blocked with 5% non-fat dry milk in Tris-buffered saline
containing 0.05% Tween 20, probed together with anti-
bodies against TfR1 (1:500) and b-tubulin (1:3000), and
then visualized with peroxidase-conjugated anti-mouse
antibody using Western Lightning Plus Chemilumines-
cence Reagent (Perkin-Elmer). Levels of ferritin in cell
lysates were determined by enzyme-linked immunosor-
bent assay (ELISA) according to the method previously
developed in our laboratory [49]. Total protein in the
cell lysates was determined using bicinchoninic acid and
the results expressed as ng ferritin/mg protein.
Measurements of VEGF
Levels of VEGF in the tissue culture media were mea-
sured using pre-coated kits (Biosource Inc., Camarillo,
CA) following the Manufacturer’s instruction. Data were
expressed as pg VEGF/ml culture media.
In vitro angiogenesis using co-cultures of cancer cells and
BCE
Cells were initially cultured separately in serum-contain-
ing growth medium; cancer cells in 24-well culture
inserts containing a 0.4 μm porous membrane, and BCE
cells in a 24-well, gelatin-coated plate. After cells were
grown to 75% confluence, the medium was replaced with
serum-free medium, and the cells were grown for an
additional 24 h. To initiate the co-culture, inserts con-
taining cancer cells were placed into wells containing
BCE cells. The porous membrane kept cells physically
separated while allowing secreted factors to pass through
the membrane and be mixed with the medium covering
the BCE cells. Prior to the co-culture, photographs of
BCE cells were taken for a reference. Twenty four h after
exposures to the factors generated by cancer cells grown
on the inserts, BCE cells were photographed again.
Statistical analysis
The experimental differences were determined by two-
tailed Student’s t-test. Graphed data represent the
means ± SD of at least three experiments except that
the IRP binding assays were done twice. A confidence
level of p < 0.05 was taken to represent a significant dif-
ference in all cases.
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